Concepedia

Viktoria Dvornichenko

VD

Statistics

Publications

4

Citations

136

H-Index

4

Active since

2017

Affiliations

Mayo Clinic in Arizona(Current)

Texas Oncology

Comprehensive Cancer Center Erlangen

Institut Gustave Roussy

Vall d'Hebron Institute of Oncology

Viktoria Dvornichenko is an author at Mayo Clinic in Arizona specializing in oncology, her2-positive breast cancer, and pharmacology.

Publications per year

2017–2023

4

Publications

4

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

, , +17

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors

Yulia A. Chapygina, Viktoria Dvornichenko, Natalia V. Zhukova et al. · Oncotarget · 2017 · 35 citations · Full text

, , +17

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch et al. · European Journal of Cancer · 2021 · 33 citations · Full text

, , +17

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Judith Balmañà, Peter A. Fasching, Fergus J. Couch et al. · Breast Cancer Research and Treatment · 2023 · 22 citations · Full text

, , +17

1–4 of 4